The small molecule inhibitors targeting CDK4 and CDK6 recuperate the impaired tumor suppression function induced by p16INK4A mutation, which revives the tumor growth in pancreatic ductal adenocarcinoma (PDAC) [20]. This evidence concerns the gene CDKN2A and pancreatic ductal adenocarcinoma.